Autopsy report · NCT02500914

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

“Strategic Considerations”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 35 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Stemcentrx

Sponsor type

Industry

Conditions

Small Cell Lung Cancer

Interventions

SC-002

Participants

35

Sites

4

Countries

United States

Trials that died the same way

• PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
  “strategic decision” (82% match in meaning)
• Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
  “Strategic reasons” (77% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (76% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (76% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.